Bayer anticipates multi-billion impairment charges from worsening outlook

摘要

Bayer foresees a lower than previously reported outlook in the agricultural market and expects mid-to-high single-digit billion-euro non-cash impairment charges in its Crop Science business.The company is confirming its overall adjusted outlook for 2020 group sales with 2021 business flat following impacts from the Covid-19 pandemic and currency effects.But sales for the Crop Science division are likely to fall in 2021.